Ann: Quarterly Cashflow Report, page-7

Excellent report.....better hurry up @druce buying script......the only direction is up now

Good manufacturing numbers coming through

Good sales ......ramping up nice revenue so far

Two new patents filed.....no doubt at least one referring to radiotherapy

The most important new information below means we will be going into phase 2 with data to be published shortly

The dose escalation phase for DEP® cabazitaxel is approaching completion with multiple patients displaying efficacy signals, including stable disease of more than 47 weeks and significant reductions in specific tumour biomarkers, such as prostate specific antigen